Rechercher | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Affichage: 2 résultats.

- Article de périodique
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan, Asher Cramer, Paula Demirkan, Fatih Fraser, Graeme Silva, Rodrigo Santucci Grosicki, Sebastian Pristupa, Aleksander Janssens, Ann Mayer, Jiri Bartlett, Nancy L Dilhuydy, Marie-Sarah Pylypenko, Halyna Loscertales, Javier Avigdor, Abraham Rule, Simon Villa, Diego Samoilova, Olga Panagiotidis, Panagiots Goy, Andre Mato, Anthony HELIOS investigators Van Den Neste, Eric[UCL] (2016) The Lancet Oncology — Vol. 17, no. 2, p. 200-211 (2016)
- Article de périodique
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
Drach, Johannes Huang, Huiqiang Samoilova, Olga Belch, Andrew Farber, Charles Bosly, André[UCL] Novak, Jan Zaucha, Jan Dascalescu, Angela Bunworasate, Udomsak Masliak, Zvenyslava Vilchevskaya, Kateryna Robak, Tadeusz Pei, Lixia Rooney, Brendan van de Velde, Helgi Cavalli, Franco (2018) Leukemia and Lymphoma — Vol. 59, no. 4, p. 896-903 (2018)